Notable Labs (NTBL) Stock Price, News & Analysis

Company Overview

Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically responsive patients prior to their treatment and enables fast-track therapeutic development in this patient population. The company's pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor to induce cell cycle arrest and apoptosis in various cancer cells; and Fosciclopirox, a pro-drug of ciclopirox for acute myeloid leukemia. Notable Labs, Ltd. was incorporated in 2014 and is headquartered in Foster City, California.

Key Stats

• Today's Range: $0.24 to $0.31
• 50-Day Range: $0.24 to $0.48
• 52-Week Range: $0.22 to $4.24
• Volume: 2.11 million shs
• Average Volume: 1.01 million shs
• Market Capitalization: $2.24 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.00
• Consensus Rating: Moderate Buy

Notable Labs Stock Analysis - MarketRank™

Notable Labs scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Notable Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Notable Labs has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Notable Labs has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NTBL.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Notable Labs does not currently pay a dividend.

Dividend Growth

Notable Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NTBL.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for NTBL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Notable Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Notable Labs is held by insiders.

Percentage Held by Institutions

70.48% of the stock of Notable Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NTBL Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Notable Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Notable Labs investors own include Algonquin Power & Utilities (AQN), LiveOne (LVO), Palatin Technologies (PTN), Frontier Group (ULCC), Adverum Biotechnologies (ADVM), Sirius XM (SIRI) and Clearside Biomedical (CLSD).

Company Calendar

• Today: 1/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NTBL
• Previous Symbol: NASDAQ:NTBL
• CUSIP: N/A
• CIK: 1603207
• Web: www.vblrx.com
• Phone: (728) 993-5000
• Fax: 972-8993-5001
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.00
• High Stock Price Target: $9.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: +2,723.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-11,260,000.00
• Net Margins: N/A
• Pretax Margin: -3,368.05%
• Return on Equity: -80.81%
• Return on Assets: -62.86%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 2.77
• Quick Ratio: 2.77

Sales & Book Value

• Annual Sales: $313,000.00
• Price / Sales: 7.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.81 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 9,018,000
• Free Float: 9,544,000
• Market Cap: $2.24 million
• Optionable: No Data
• Beta: 0.98